<DOC>
	<DOCNO>NCT00886522</DOCNO>
	<brief_summary>The purpose study evaluate engraftment donor hemopoiesis ( proportion transplant patient successful engraftment day +42 ) adult patient affect high risk hematological malignancy intrabone infusion cord blood .</brief_summary>
	<brief_title>Intrabone Infusion Cord Blood Adults With Hematological Malignancies</brief_title>
	<detailed_description>For many hematological malignancy , hemopoietic stem cell ( HSC ) transplant possible treatment . The source HSC often bone marrow ( BM ) , past 10 year , peripheral blood cell ( PBSC ) mobilize granulocyte growth factor . Transplant need HLA compatible ( relate unrelated ) donor . Around 10-30 % patient indication allogeneic HSC transplant able undergo procedure lack HLA compatible donor . Cord blood ( CB ) cell represent another possible source , need low degree HLA compatibility , type transplant , however , offer low number HSC . For reason , adult patient , , could use source , suitable number cell per kg , recipient body weight . Recently , experimental animal model observe intrabone HSC transplant allow , recipient , engraftment donor hemopoiesis use 1Log ( 10-1 ) low number cell compare intravenous way ( Yahata 2003 , Castello 2004 ) . Safety feasibility intrabone infusion verify two clinical study human : first conduct Ringden O. et al . 18 patient without evidence collateral effect complete engraftment donor hemopoiesis BM source HSC ( Hagglund 1998 ) ; second one conduct Frassoni et al . ( Frassoni 2008 ) CB source HSC . The aim study evaluate intrabone infusion instead intravenous one , HSC transplant CB patient haematological malignancy possible find HLA match donor . We perform : - evaluation engraftment kinetics ; - evaluation chimerism degree 30 , 60 , 100 day , 6 month 1 year transplant ; - study immunological reconstitution role NK compartment .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>Age 18 65 year . Patients affect hematological malignancy without HLA identical sibling donor unrelated donor . Informed consent . Patients ECOG &lt; 2 . Patients blood creatine &gt; 2 mg/dl transaminase cholestase index &gt; 5 time compare normality upper limit . Patients Cardiac Fraction Ejection &lt; 40 % . Patients DLCO &lt; 60 % Diffusing Lung Capacity carbon monoxide attest severe pulmonary insufficiency . Patients peripheral blast cell count 10 % . Second neoplasia diagnose 2 year . Patients active suspected infection fungi therapeutic treatment ongoing . HIV positive patient . HCVRNA HBVRNA positive patient ( possible enrol discussion Principal Investigator ) . Pregnant lactating woman . Severe mental disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Anti-thymocyte globulin Fresenius</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Cord blood</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Human Leucocyte Antigen</keyword>
	<keyword>Hematopoietic Stem Cell</keyword>
	<keyword>Hematopoietic Stem Cell Transplant</keyword>
	<keyword>Graft-versus-Host-Disease</keyword>
	<keyword>Graft-versus-Host-Disease prophylaxis</keyword>
	<keyword>Intrabone infusion</keyword>
	<keyword>Thiotepa</keyword>
</DOC>